Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 8Urogenital Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Diseases 1Pheochromocytoma 1Paraganglioma 1Oligometastatic Prostate Cancer (OMPC) 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm Metastasis 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lymphatic Diseases 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immune System Diseases 1Gastro-enteropancreatic neuroendocrine tumor 1Digestive System Neoplasms 1Breast Neoplasms 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1AIDS-Related Complex 1

Interventions

pembrolizumab 2radium Ra 223 dichloride 1enzalutamide 1efineptakin alfa 1abiraterone 1Radium-223 1Pluvicto 1PSMA-11 1Lutetium-177 1Lutetium 1Injections 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Castration-resistant Prostate Cancer (mCRPC) × Lutetium-177 × Clear all
NCT07244393 2025-11-24

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Cellbion Co., Ltd.

Phase 1 Not yet recruiting
30 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡